The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Highlights for patients with relapsed/refractory AML

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Norbert Vey, Institut Paoli-Calmettes, Marseille, FR, about the highlights for patients with relapsed/refractory (R/R) AML from ASH 2020.

ASH 2020: Highlights for patients with relapsed/refractory AML

Despite progress, the treatment of R/R AML is still challenging. In this video, Vey underlines preliminary findings of studies, reported at ASH 2020, evaluating new regimens for R/R AML. 

 

Share: